4.07
0.00 (0.00%)
| Previous Close | 4.07 |
| Open | 4.07 |
| Volume | 546,633 |
| Avg. Volume (3M) | 394,657 |
| Market Cap | 492,522,944 |
| Price / Sales | 19.34 |
| Price / Book | 1.62 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Operating Margin (TTM) | -473.73% |
| Diluted EPS (TTM) | -0.620 |
| Quarterly Revenue Growth (YOY) | -23.80% |
| Total Debt/Equity (MRQ) | 8.17% |
| Current Ratio (MRQ) | 4.62 |
| Operating Cash Flow (TTM) | -44.91 M |
| Levered Free Cash Flow (TTM) | -13.94 M |
| Return on Assets (TTM) | -13.76% |
| Return on Equity (TTM) | -20.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | OmniAb, Inc. | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.89% |
| % Held by Institutions | 68.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avista Capital Holdings, L.P. | 30 Jun 2024 | 15,817,934 |
| Chicago Capital, Llc | 30 Sep 2024 | 3,162,555 |
| First Sabrepoint Capital Management Lp | 30 Jun 2024 | 1,875,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 170.27%) | Buy |
| Median | 9.50 (133.42%) | |
| Low | 8.00 (Benchmark, 96.56%) | Buy |
| Average | 9.50 (133.42%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.07 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 14 Nov 2024 | 8.00 (96.56%) | Buy | 4.07 |
| HC Wainwright & Co. | 14 Nov 2024 | 11.00 (170.27%) | Buy | 4.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2024 | Announcement | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights |
| 30 Oct 2024 | Announcement | OmniAb to Participate in Two Investor Conferences in November |
| 22 Oct 2024 | Announcement | OmniAb to Report Third Quarter 2024 Financial Results on November 12 |
| 26 Aug 2024 | Announcement | OmniAb to Participate in Two Investor Conferences in September |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |